Zavicefta 2 g/0.5 g powder for concentrate for solution for infusion

DRUG3 trials

Sponsors

Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla, National University Of Singapore, Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico

Conditions

Bacteriemia producida por P. aeruginosa.Bloodstream InfectionPatients colonized with CPE undergoing liver transplantation (LT)Ventilator Associated Pneumonia and Hospital-Acquired Pneumonia

Phase 3

Targeted versus standard peri-operative prophylaxis in patients colonized with carbapenemase-producing Enterobacterales undergoing liver transplantation: a stepped-wedge cluster randomization trial

Not yet recruitingCTIS2025-523453-34-00

Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere ScientificoPatients colonized with CPE undergoing liver transplantation (LT)

Target: 168Updated: 2026-08-31

Phase 4

Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia produced by Pseudomonas aeruginosa: a multicenter, randomized (SHORTEN-2) clinical trial with a DOOR/RADAR analysis.

Not yet recruitingCTIS2023-508441-41-00

Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De SevillaBacteriemia producida por P. aeruginosa.

Target: 306Updated: 2025-07-25

EaRly impAct theraPy with ceftazidime-avibactam via rapID diagnostics versus standard of care antibiotics and diagnostics in patients with bloodstream infection, hospital-acquired pneumonia or ventilator-associated pneumonia due to Pseudomonas aeruginosa or carbapenemase producing Enterobacterales ("RAPID")

Not yet recruitingCTIS2024-520067-13-00

National University Of SingaporeBloodstream Infection, Ventilator Associated Pneumonia and Hospital-Acquired Pneumonia

Target: 80Updated: 2026-04-29